tbuckley/cabot-search huggingface dataset:
944TiP Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and/or metastatic head and neck squamous cell carcinoma : The IMPORTANCE trial
Authors: B.F. Tamaskovics, M. Hecht, P. Schubert, A. Kallies, T. Illmer, J. Radke, O. Koelbl, F. Steger, T.B. Brunner, C. Rödel, M. Fleischmann, A. Reinacher-Schick, L.F. Wingender, P. Melchior, G. Klautke, U. Hintzen, U.S. Gaipl, J. Haussmann, W. Budach, R. Fietkau
Journal: Annals of Oncology (2023)
934P Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Authors: H. Gong, S. Tian, H. Ding, L. Tao, L. Wang, J. Wang, T. Wang, M. Zhang, Y. Shi, C. Xu, C. Wu, S. Wang, L. Zhou
Journal: Annals of Oncology (2023)
962P SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Authors: W. Yan, None C. xiao, X. Liu, Y. Li, J. Wu, B. Qu
Journal: Annals of Oncology (2023)
957P Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Authors: M. Li, J. Yue, B. Zhang, X. Shi, K. Cui, J. Liu, Z. Li, L. Zhao
Journal: Annals of Oncology (2023)
946P Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Authors: S. Lu, W. Zhang, J. Li, B. Hu, X. Li, Z. Liu, T. Wan, H. Tang, B. Liu, Y. Cao, T. Jiao, Z. Zhang, Y. Wang, B. Gao, Y. Liu
Journal: Annals of Oncology (2023)
937P Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment
Authors: M. Jové, I. Braña, M. Oliva Bernal, A. Hernando Calvo, C. Erasun Lecuona, J.D. Assaf Pastrana, A. Mato-Berciano, M.V. Maliandi, S. Torres-Manjon, R. Moreno, C. Le, P.G. Nuciforo, R. Alemany, G. Capella, C. Blasco, M. Cascallo Piqueras, R. Mesia Nin
Journal: Annals of Oncology (2023)
925P Treatment discontinuation of immune checkpoint blockade in patients with head and neck squamous cell carcinoma experiencing complete or nearly complete remission
Authors: K. Klinghammer, B. Heinze, P. Ivanyi, M. Pogorzelski, S. Laban, J. Raguse, S. Ochsenreither, U. Keller, U. Keilholz, D.A. Hahn
Journal: Annals of Oncology (2023)
958P Preliminary results of radiotherapy (RT) combined with sintilimab (Sin) and bevacizumab (Bev) in advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICIs): A prospective phase II study
Authors: None J. xue, None J. tang, None Z. lin, J. Wang, None J. zhang, T. Zhang
Journal: Annals of Oncology (2023)
926P UK national real-world outcome data of first-line pembrolizumab treatment in head and neck squamous cell cancer (HNSCC)
Authors: I. Vasiliadou, D. Grose, A. Hartley, S. Partridge, A. Haridass, A. Williamson, D. Noble, H. Walter, E. De Winton, J. Cohen, K. Geropantas, O. Donnelly, P. Jankowska, R. Moleron, D. Ulahannan, A. Michaelidou, S. Raouf, S. Khalique, S. Bhide, A. Kong
Journal: Annals of Oncology (2023)
963P Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Authors: M. Pan, C. Wang, W. Xie, K. Zhao, S. Fang, Q. Zhou, J. He, M. Deng, Y. Yang, W. Wang, Q. Zhang, S. Bao
Journal: Annals of Oncology (2023)
932P Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Authors: L. Ugidos De La Varga, N. Ruiz del Arbol, G. Hernández-Ibarburu, E. Delia, P. Peinado, M. Torres Velasco, R. Alvarez Gallego, C.G. Munoz Sanchez-Miguel, M. Garcia Morillo, C. Toledano, A. Cubillo
Journal: Annals of Oncology (2023)
955P IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Authors: A. Vogel, A. Saborowski, G.M. Siegler, J. Siebler, U. Lindig, M. Schultheiss, T. Mueller, H. Simon, C. Jöckel, D.W. Müller, S-E. Al-Batran, E. De Toni
Journal: Annals of Oncology (2023)
941P Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Authors: S.Y. Jang, Y-G. Lee, S.H. Chun, J.H. Park, K.U. Park, H. Chang, K-W. Lee, H.R. Kim, S-H. Shin, H.J. An, K-E. Lee, I.G. Hwang, M-J. Ahn, S-B. Kim, B. Keam
Journal: Annals of Oncology (2023)
945MO AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC)
Authors: Z. Ren, Y. Huang, Y. Guo, M.M. Hou, W. Wang, M. Kuang, C. Hao, W. Wang, Y. Zhang, T. Song, C. Dai, K. Hsing-Tao, V. Li, R. Abdrashitov, L. Wang, J. Fan
Journal: Annals of Oncology (2023)
959P Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Authors: L. Ma, Y. Zhang, Y. Fang, C. Hao, Q. Fan, D. Jiang, L. Lu, F. Su, C. Yang, Z. Liu, J. Tian, X. Sun, S. Sun, Y. Cheng
Journal: Annals of Oncology (2023)
948P Phase (Ph) I/II study of sitravatinib (Sitra) alone or with tislelizumab (TIS) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/GEJC)
Authors: J. Li, Y. Bai, Z. Chen, J. Ying, Y. Guo, W. Fang, F. Zhang, J. Xiong, T. Zhang, Z. Meng, J. Zhang, F. Yu, J. Zhang, Z. Zhang, S. Qin
Journal: Annals of Oncology (2023)
924P Polyfunctional HPV16-Specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC)
Authors: K.J. Harrington, J. Weiss, K. Price, J. Kaczmar, D. Schaaf, N. Riebel, S. Jones, A. Cotty, S.G. McCarthy, L.V. Wood
Journal: Annals of Oncology (2023)
943TiP PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)
Authors: N. Saba, H. Youssoufian, E. Cohen, J. Singh, L. Makris, M. Perdomini, S. MacIntyre, A. Denker
Journal: Annals of Oncology (2023)
968P High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Authors: K.N. Kwok, K.M. Cheung, S.J.L. Lam, H.S. Lam, S.M. Yip, S. Lam, O.P. Chiu, P.Y.M. Woo, W. Sung, J. Chow, K. Bao, G.T.C. Cheung, A.K.Y. Chan, E.Y.H. Fong, S.K.K. Ng, K.C.M. Cheung, H.L. Leung, D. Kan, H.H.Y. Yiu, D.C.C. Lam
Journal: Annals of Oncology (2023)
930P Platinum and taxane (PT) plus immunotherapy versus immunotherapy alone in patients with recurrent/metastatic (R/M) head and neck cancer (HNSCC)
Authors: M. Bonomi, B. Klamer, P. Bhateja, H. Abu-Sbeih, F. Rind, S. Baliga, D. Konieczkowski, E. Gogineni, K. Dibs, A. Faieta, J. Grecula, M. Old, R. Carrau, J. Rocco, D. Blakaj, M. Issa
Journal: Annals of Oncology (2023)
947P The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Authors: L. Bai, Y. Bai, M. Huang, G. Shao, L. Song, M. Sun, W. Wang, J. Wu, A. Xu, L. Huang, T. Liu, W. Liu, Z.M. Wang, B. Li, Y. Xia
Journal: Annals of Oncology (2023)
938P Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Authors: C. Le Tourneau, C. Even, S. Salas, Y. Pointreau, P. Ceruse, E. Babin, J. Fayette, V. Rondeau, V. Grumberg, F-E. Cotté, A. Govart, K. Baumstarck, J. Guigay
Journal: Annals of Oncology (2023)
952P Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Authors: G. Shao, H. Zeng, B. Sun, K. Zhu, T. Song, T. Si, J. Ji, S. Gu, R. Liu
Journal: Annals of Oncology (2023)
933P Real-world patterns of immunotherapy utilization and outcomes in recurrent/metastatic head and neck cancer (R/M HNC) patients across European countries: A multicenter retrospective federated analysis
Authors: G. Plavc, R.S. Calisto, C. Paratore, M.J. Lostes Bardaji, E. Hallan Naderi, T. Rutkowski, A. Kovac, A. Cortez, G. Pretelli, I. Braña, C. Vieira, M.J. Bento, K. Kolenc Mokotar, M. Di Maio, P. Sperone, F. Vignani
Journal: Annals of Oncology (2023)
940P Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Authors: K. Saleh, M. Texier, M. Iacob, A. Daste, J. Fayette, G. Lefebvre, E.B. Saada, S. Zanetta, M. Vinches, C. Toullec, S. Salas, M-C. Kaminsky-Forrett, A.C. Johnson, C. Sire, None N. Khalife-saleh, F.R. Ferrand, L. Monard, A. Auperin, C. Even
Journal: Annals of Oncology (2023)
935P A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
Authors: R. Galot, C. Le Tourneau, L.F.L. Licitra, C. Even, A. Daste, S. Henry, C. Borel, C. Abdeddaim, E. Seront, J.B. Prevost, A. Rutten, E.B. Saada, F. Rolland, L. Livi, P.M.C. Specenier, J. Leys, C. Olungu, C. Fortpied Lefevre, A. Joaquim, J-P. Machiels
Journal: Annals of Oncology (2023)
951P HAIC combined with anlotinib and TQB2450 as adjuvant therapy for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after hepatectomy: A single-centre, non-randomised, open clinical study
Authors: T. Zhang, L. Wang, None Y. zhao, Q. Pan, A. Mao, W. Zhu, N. Zhang, Y. Zhang
Journal: Annals of Oncology (2023)
960P Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Authors: M. Abdelrahim, A. Esmail, A.R. He, J. Franses, I. Bhan, D.W. Victor, S. Kodali, A.A. Connor, A. Saharia, C. Brdiges, T. Tin, C. Brewer, A. Jurdi, M.C. Liu, R.M. Ghobrial
Journal: Annals of Oncology (2023)
931P Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) patients
Authors: P. Pitakpaiboonkul, C. Jiarpinitnun, P. Pattaranutaporn, N. Ngamphaiboon
Journal: Annals of Oncology (2023)
942P Response to salvage chemotherapy with paclitaxel +/- cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (CeTax study)
Authors: R.G. Herrera Gomez, K. Saleh, E. Auclin, M. Vinches, C. Gervais, V.G. Espeli, S.I. Rothschild, C. Even, V. Cristina
Journal: Annals of Oncology (2023)
949P Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Authors: B-K. Li, Y. Yuan, L. Qiao, W. He, G. Wang, H. Chen, B. Zhang, H. Fuxi, J. Qiu
Journal: Annals of Oncology (2023)
929P Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with with recurrent/ metastatic head and neck squamous-cell carcinoma (R/M SCC) of the nasal cavity and paranasal sinuses
Authors: L. Gui, Y-K. Shi, P. Liu, None J. Yang, X. He
Journal: Annals of Oncology (2023)
994P Regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world (RW) practice: Final analysis of the prospective, observational REFINE study by prior liver transplantation (PLT)
Authors: M. Pinter, Y.J. Kim, P. Merle, R.S. Finn, J. Khan, K. Ozgurdal, S. Qin
Journal: Annals of Oncology (2023)
1002P Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Authors: K. Tan, X. He, L. Zang, Y.H. Nan, H.Z. Luo, None Y.C. gong, L. Bai, G. Dou, X. Du
Journal: Annals of Oncology (2023)
999P Donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II trial (DoHAICs study)
Authors: W. Zhang, W. Gao, C. Liu, G. Li, Q. Zhang, H. Zhou, F. Fang, H. Li, Y. Cui, Q. Wu, X. Zhu, Q. Li, N. Zhang, T. Song, W. Lu
Journal: Annals of Oncology (2023)
969P Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Authors: K.M. Cheung, K.N. Kwok, S.J.L. Lam, H.S. Lam, S.M. Yip, S. Lam, O.P. Chiu, L. Sutanto, J.C.H. Chan, A.K.Y. Chan, S.K.K. Ng, J.C.S. Ho, C.C.C. Chan, J.C.K. Yung, H.L. Leung, P.Y.M. Woo, H.H.Y. Yiu, D.C.C. Lam
Journal: Annals of Oncology (2023)
1022MO Predicting overall survival of patients with melanoma and NSCLC treated with immunotherapy using AI combining total tumor volume and tumor heterogeneity on CT-Scans
Authors: L. Dawi, S. Ammari, Y. Belkouchi, J. Hadchiti, L. Lawrance, F. Wirth, A. Bertin, S. Morer, N. Billet, C. Balleyguier, P-H. Cournede, None H. Talbot, N. Lassau
Journal: Annals of Oncology (2023)
979P Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Authors: M.E. Reig Monzon, N. Luque Caro, J. Bruix, C. Gomez Martin, B. Sangro, J. Sastre Varela, J.M. Ordoñez Tres, J. Argemi, R. Perez Lopez, M.P. Torres Candela, J.L. Lledó-Navarro, A.M. Matilla Peña, J-L. Montero, R.A. Pazo Cid, M. Varela
Journal: Annals of Oncology (2023)
1004P Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Authors: D. Song, L. Zheng, A. Zhang, F. Cao, W. Hao, Z. Zhao, J. Zheng, D. Lu
Journal: Annals of Oncology (2023)
1030P Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Authors: E. Calvo, E. Garralda, G. Alonso, V. Gambardella, E.E. Parkes, J. Thompson, R. Latek, P. Sikken, M. Schmohl, K.J. Harrington
Journal: Annals of Oncology (2023)
1016O Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC
Authors: L. Flatz, M. Frueh, V. Walter, A-K. Jochum, S. Diem, E. Jaeger, C. Antonio, C. Schürch, C. Driessen, M. Brutsche, J. Walz, H-G. Rammensee, B. Becher, A. Tufman, N. Nunez, M. Joerger, L. Zender, H. Läubli, F. Berner, N. Wyss
Journal: Annals of Oncology (2023)
1037P Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors
Authors: N. Mach, C. Belli, E. Fernandez, W. Alsdorf, I. Colombo, S. Dakhel, T. Hemmerle, E. Puca, C. Libbra, S. Mulatto, J.C. Mock, K. Lorizzo, D. Neri, A. Covelli, U. Lauer, J.C. Hassel, A. Stathis, W.M. Fiedler, G. Curigliano
Journal: Annals of Oncology (2023)
1031P ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors
Authors: E. Calvo, M. Joerger, H. Läubli, J.S. Lopez, G. Alonso, E. Corral de la Fuente, D. Hess, D. König, V. Perez, E. Gasal, S. Jethwa, D. Di Blasi, E. Garralda
Journal: Annals of Oncology (2023)
997P A practical risk classification of early recurrence and long term survival outcomes in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy: A decision tree analysis
Authors: R.Y. Mai, R. Liang, Y. Lin, B-D. Xiang, L. Ma, F-X. Wu, G. Wu, L-Q. Li, J. Ye
Journal: Annals of Oncology (2023)
989P Disease etiology and efficacy outcomes with atezolizumab plus bevacizumab (atezo-bev) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Multinational retrospective analysis
Authors: S. Kim, S.Y. Lee, Y.G. Park, H-D. Kim, J.J.X. Lee, M.H. Ryu, B-Y. Ryoo, D.W.M. Tai, C. Yoo
Journal: Annals of Oncology (2023)
1024MO Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate with severe immune-related adverse events (irAE) and progressive disease (PD) in patients with melanoma treated with anti-PD-1-based therapy
Authors: D. Jimenez-Sanchez, E.M. Will, J. Lai, G. Warrier, E.J. Lipson, J.S. Deutsch, A.S. Szalay, J. Taube
Journal: Annals of Oncology (2023)
971P Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Authors: Z. Fan, T. Yang, L-H. Gu, W. Qiu, Y-J. Liang, X-M. Wang, F. Shen, C. Li, M. Wang
Journal: Annals of Oncology (2023)
988P Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Authors: A.H. Allam, A.A. Bahbah, M.I. Ewis, L.N. Sherif, M. Mohamed Shawqi, O.A. Aboshady, M.T. KhalafAllah
Journal: Annals of Oncology (2023)
1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors
Authors: T.U. Marron, J.G. Misleh, None C. chen, Z.A. Wainberg, J. Powderly, R. Boccia, M. Gordon, J. Segar, I. Csiki, J.M. Schanzer, L. O'Toole, N. Huang, J. Seppa, J. Glenn, K. Klumpp, A.I. Spira
Journal: Annals of Oncology (2023)
1035P Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors
Authors: H.Y. Lim, J.S. Ahn, J.O. Park, J. Yong Hong, H. Seon, J.K. Lee, S.Y. LEE, H.T. Kim
Journal: Annals of Oncology (2023)
1027P An open-label, multicenter, phase I/II study of GI-101, CD80-IgG4 Fc-IL2v, in advanced solid tumors (Part A of GII-101-P101; KEYNOTE-B59)
Authors: B.C. Cho, J-L. Lee, B. Shim, S.J. Shin, H.J. Lee, J-Y. Lee, J. Powderly, S. Lee, N. Yun, M. Ham, K.E. Lee, None W.Y. lee, H. Kang, M.H. Jang
Journal: Annals of Oncology (2023)
966P Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Authors: T. Payo-Serafín, P. Fernández Palanca, C. Méndez Blanco, B. San-Miguel, M.J. Tuñón, J. González-Gallego, J.L. Mauriz
Journal: Annals of Oncology (2023)
973P Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Authors: S. Lee, S. Chamseddine, None R. hiatia, Z.I. Hu, A. Mahvash, J.N. Vauthey, H.S. Tran Cao, Y.S. Chun, C-W.D. Tzeng, T. Newhook, E.B. Ludmir, P. Habibollahi, Z. Metwalli, A. Kaseb
Journal: Annals of Oncology (2023)
1019O Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors
Authors: V. Moreno Garcia, E. Calvo, A. Asch, M. Butler, J. Zugazagoitia, J. Charlson, A. Cervantes, B. Van Tine, D. Aggen, J. Clarke, M. Johnson, M. Wileman, A. Liddle, R. Naidoo, F. Brophy, M. Rosenberg, D. Jolliffe, D. Williams, E. Norry, D. Hong
Journal: Annals of Oncology (2023)
1003P Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Authors: O.P. Maaño, J.M.V. Malbas, C. Dy
Journal: Annals of Oncology (2023)
1021MO Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors
Authors: M. Mckean, E.E. Dumbrava, O. Hamid, P. Merriam, J.A. Call, W. Feely, A. Green, U.N. Vaishampayan, K.N. Moore, S. Weroha, S. Krishnan, A. George
Journal: Annals of Oncology (2023)
1033P First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors
Authors: A. Naing, J.C. Park, S.J. Klempner, S. Khan, P. Pearson, J. Lufkin, P. Keller, H. Youssoufian, A. DeCillis, I. Mazo, D. Sommerhalder
Journal: Annals of Oncology (2023)
978P Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Authors: C.A.M. Fulgenzi, Y-H. Huang, A. Saeed, L. Rimassa, M. Schoenlein, F. Piscaglia, A. Kaseb, A. Vogel, D. Bettinger, M. Silletta, M. Kudo, C. Vivaldi, B. Scheiner, S. Ulahannan, P.R. Galle, W-F. Hsu, A. Parisi, H.J. Chon, D.J. Pinato, C. Ang
Journal: Annals of Oncology (2023)
977P Hepatic arterial infusion chemotherapy (HAIC) combined with Regorafenib and PD-1 inhibitors versus Regorafenib combined with PD-1 inhibitors for second-line treatment Hepatocellular carcinoma (HCC)
Authors: N. You, X. Peng, J. Li, L. Wang, K. Wu, L. Zheng, D. Li, Z. Chen, H. Zhang, P. Huang, Y. Wang, R. Liao, Q. Li, P. Guo, W. Wang
Journal: Annals of Oncology (2023)
1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity
Authors: F. Wang, C-Y. Lin, J-M. Sun, C-H. Lu, X. Zhu, Z. Chen, I-H. Kim, Y. Pan, J. Zhang, Z. Chen, D. Tougeron, S-B. Kim, E. Van Cutsem, R. Abdrashitov, R. Ge, J. Sun, J. Zhou, R-H. Xu
Journal: Annals of Oncology (2023)
1028P Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors
Authors: D. Day, V. Ganju, K. Chung, L. Si, L. Mao, M. Aghmesheh, R. Hoyer, K. Brewin, S. Zeng, Q. Lu, C. Jiang, F. Ren, X. Wu, J. Guo
Journal: Annals of Oncology (2023)
972P Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Authors: M. Persano, M. Rimini, T. Tada, G. Suda, S. Shimose, M. Kudo, J. Cheon, F. Finkelmeier, J. Presa, G. Masi, C. Yoo, S. Lonardi, F. Piscaglia, M.A. iavarone, E. TAMBURINI, G. Cabibbo, M. Silletta, S. Cascinu, M. Scartozzi, A. Casadei Gardini
Journal: Annals of Oncology (2023)
993P Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Authors: H. Chon, Y.S. Song, H. Yang, I. Kim, K. Hye-young, W.S. LEE, Y.B. Sang, C. Kim
Journal: Annals of Oncology (2023)
996P Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Authors: X. Duan, H. Li, G. Zhang, D. Kuang, Y. Li, X. He, C. Xing, Y. Wang, M. Shi, J. Ren, X. Han
Journal: Annals of Oncology (2023)
1039P First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
Authors: G. Ku, L. Shen, S.J. Klempner, H. Pan, J. Kratz, X. Liang, Y. Deng, S. Kim, Z. Wang, L. Feller, J. Powderly, F. Dayyani, R.E. Schneider, E. Girda, J.D. Berlin, K. Spencer, M.T. Nguyen, V. Wang, C. Xu, A. Zhu
Journal: Annals of Oncology (2023)
975P The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Authors: K. Tsuchiya, M. Yamada, Y. Yasui, Y. Yamazaki, N. Uchihara, K. Suzuki, Y. Tanaka, H. Miyamoto, T. Keitoku, R. Okada, M. Higuchi, K. Takaura, S. Tanaka, C. Maeyashiki, N. Tamaki, H. Nakanishi, M. Kurosaki, N. Izumi
Journal: Annals of Oncology (2023)
1026MO A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors
Authors: R-H. Xu, L. Huiyan, H. Zhao, W. Wei, D. Ma, X. Yin, Y. Ni, Y. Wang, Y. Zhang, J. Zhou, H. Pan, Z. Niu, J. Zhang, H. Ren, M. Kang, W. Jia, S. Gu, P. Liu, Z. Zhang, S. Wang
Journal: Annals of Oncology (2023)